FOCUS4 � Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme

The primary objectives are: 1) For patients with the same tumour type (characterised by the results of the molecular tests), do the proposed new agents significantly increase the length of time for a patient to die, or for their tumour to increase in size by at least 20% when compared to patients having a treatment break after their first-line chemotherapy, in the time period after standard first-line? 2) Do the patients who have a particular genetic mutation identified by the molecular tests respond better to a proposed new agent than the patients who do not have that particular mutation?